In vivo use of selective TP receptor antagonists improve vascular dysfunction, stiffness, and arterial remodelling in angiotensin II-induced hypertension [64] and inhibits atherogenesis in Apoe−/−-deficient mice [82]. The gene discussed is AGT; the disease is Hypertension.